Nectar Lifesciences Limited NECLIFE NSEPHARMA
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -184.6% CAGR over 5 years.
- Trading 54.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NECLIFE Nectar Lifesciences Limited NSEPHARMA | 12.45 | - | ₹241.85 Cr | - | -8.24% | -7.46% | 0.02% | -184.62% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 428.91 Cr | 280.67 Cr | 5.00 Cr | 0 |
| Cost of Revenue | - | 0 | 665.80 Cr | 263.54 Cr | 3.35 Cr | 0 |
| Gross Profit | - | 0 | -236.90 Cr | 17.13 Cr | 1.64 Cr | 0 |
| Operating Expenses | - | 11.26 L | -66.84 Cr | 95.53 Cr | 2.17 Cr | 1.99 Cr |
| Operating Income | - | -11.26 L | -170.06 Cr | -78.41 Cr | -53.24 L | -1.99 Cr |
| EBITDA | - | 42.18 L | -151.75 Cr | -61.54 Cr | -30.21 L | 86.89 Cr |
| Interest Expense | - | 0 | 20.15 Cr | 18.70 Cr | 0 | 30.22 Cr |
| Pretax Income | - | 35.20 L | -187.66 Cr | -96.75 Cr | -50.62 L | 56.60 Cr |
| Tax Provision | - | 12.30 L | -57.58 Cr | -33.52 Cr | -17.69 L | -11.02 Cr |
| Net Income | - | 7.84 Cr | -130.09 Cr | -63.23 Cr | -32.93 L | 14.27 Cr |
| Diluted EPS | -0.25 | 0.35 | - | -2.82 | -7.85 | 0.64 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 1,668.83 Cr | 1,523.67 Cr | 1,684.09 Cr | 1,669.97 Cr |
| Cost of Revenue | 1,369.51 Cr | 1,331.43 Cr | 1,386.88 Cr | 1,531.23 Cr |
| Gross Profit | 299.33 Cr | 192.24 Cr | 297.21 Cr | 138.74 Cr |
| Operating Expenses | 197.73 Cr | 197.42 Cr | 204.82 Cr | 227.58 Cr |
| Operating Income | 101.60 Cr | -5.17 Cr | 92.38 Cr | -88.83 Cr |
| EBITDA | 160.99 Cr | 99.50 Cr | 168.61 Cr | -22.09 Cr |
| Interest Expense | 69.94 Cr | 82.80 Cr | 89.62 Cr | 77.05 Cr |
| Pretax Income | 34.08 Cr | -42.42 Cr | 18.27 Cr | -161.53 Cr |
| Tax Provision | 9.03 Cr | -18.24 Cr | 13.27 Cr | -47.85 Cr |
| Net Income | 25.05 Cr | -24.18 Cr | 5.00 Cr | -113.68 Cr |
| Diluted EPS | 1.12 | -1.08 | 0.22 | -5.07 |
Compounded Sales Growth
| 5 Years: | 0.02% |
| 1 Year: | -98.20% |
Compounded Profit Growth
| 5 Years: | -184.62% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -54.08% |
| 6 Months: | -18.04% |
| 3 Months: | +1.30% |
| 1 Month: | +0.32% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Total Assets | 2,390.83 Cr | 2,189.21 Cr | 2,191.06 Cr | 2,047.22 Cr |
| Current Assets | 1,354.85 Cr | 1,231.18 Cr | 1,283.83 Cr | 1,237.59 Cr |
| Cash & Equivalents | 17.77 Cr | 17.55 Cr | 19.79 Cr | 19.21 Cr |
| Inventory | 659.86 Cr | 672.60 Cr | 709.15 Cr | 690.16 Cr |
| Receivables | 446.98 Cr | 279.61 Cr | 379.19 Cr | 345.49 Cr |
| Total Liabilities | 1,302.93 Cr | 1,124.62 Cr | 1,121.80 Cr | 1,091.11 Cr |
| Current Liabilities | 1,003.83 Cr | 890.93 Cr | 972.82 Cr | 1,021.54 Cr |
| Long Term Debt | 291.07 Cr | 226.47 Cr | 140.31 Cr | 60.13 Cr |
| Total Debt | 859.93 Cr | 753.83 Cr | 635.54 Cr | 582.02 Cr |
| Total Equity | 1,087.90 Cr | 1,064.59 Cr | 1,069.25 Cr | 956.11 Cr |
| Shares Outstanding | 22.43 Cr | 22.43 Cr | 22.43 Cr | 22.43 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 95.00 Cr | 133.65 Cr | 224.69 Cr | 169.44 Cr |
| Investing Cash Flow | 16.64 Cr | 51.70 Cr | -17.02 Cr | -41.93 Cr |
| Financing Cash Flow | -119.38 Cr | -185.58 Cr | -205.44 Cr | -128.09 Cr |
| Capital Expenditure | -24.97 Cr | -30.06 Cr | -29.41 Cr | -43.80 Cr |
| Free Cash Flow | 70.03 Cr | 103.59 Cr | 195.27 Cr | 125.64 Cr |
| Net Change in Cash | -7.73 Cr | -22.80 L | 2.23 Cr | -58.40 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Gross Margin % | 17.9% | 12.6% | 17.6% | 8.3% |
| Operating Margin % | 6.1% | -0.3% | 5.5% | -5.3% |
| Net Margin % | 1.5% | -1.6% | 0.3% | -6.8% |
| ROE % | 2.3% | -2.3% | 0.5% | -11.9% |
| ROCE % | 7.3% | -0.4% | 7.6% | -8.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NECLIFE